Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...
But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...
Phase 1 data indicate Intellia’s medicine could be a powerful treatment for a cardiac form of ATTR amyloidosis. But rival drugs are further ahead.
Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...
Chardan raised the firm’s price target on Intellia Therapeutics (NTLA) to $91 from $88 and keeps a Buy rating on the shares. The company ...
Intellia Therapeutics ( (NTLA) ) just unveiled an announcement.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top ...
In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...
Ken Hawkins, a retired teacher from Grants Pass, is first Oregon participant in phase 3 clinical trial Ken Hawkins, a 77-year ...
Dantech Corporation, an AWS partner since 2017, will join other industry leaders at AWS re:Invent 2024, taking place between December 2-6 at the Venetian in Las Vegas. Dantech will also be celebrating ...
Vaderis Therapeutics AG (Vaderis), a clinical stage biotechnology company focusing on treatments for rare diseases associated with vascular malformations, today announces that the US Food and Drug ...
In one of the most closely-watched arenas in biotech, Intellia says its gene editing treatment for a heart muscle ...
Alnylam's nucresiran showed promising results in Phase 1 trial for rare cardiomyopathy, achieving up to 96% TTR reduction at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback